Format

Send to

Choose Destination
Metab Brain Dis. 2019 Feb;34(1):39-52. doi: 10.1007/s11011-018-0344-x. Epub 2018 Nov 22.

Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review.

Author information

1
Neuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil.
2
School of Medicine, University Center Christus-Unichristus, Fortaleza, Ceará, Brazil.
3
Department of Seine Saint Denis, Ville Evrard Psychiatric Hospital, Paris, France.
4
Laboratory of Pathophysiology of Psychiatric Diseases, Center for Psychiatry and Neurosciences, INSERM U894, University Paris Descartes, Paris, France.
5
Department of Anesthesiology, Dr. Jose Frota Institute Hospital/IJF, Fortaleza, Brazil.
6
Neuropsychopharmacology Laboratory, Drug Research and Development Center, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Coronel Nunes de Melo Street, 1127, Fortaleza, CE, 60431-270, Brazil. silvania_vasconcelos@yahoo.com.br.

Abstract

Despite the existence of many preclinical studies, scientific evidence is lacking on the clinical use of alpha-lipoic acid (ALA) for central nervous system disorders. Therefore, we aimed at revising the literature concerning the use of ALA for the treatment of psychiatric and neurological conditions and to point out what is missing for the introduction of this antioxidant to this purpose. For this systematic review we performed a search using PubMed and SCOPUS databases with the following keywords: "alpha-Lipoic Acid AND central nervous system OR psychiatric disorders OR neurological disorders OR mood disorders OR anxiety OR psychosis OR Alzheimer OR Parkinson OR stroke". The total number of references found after automatically and manually excluding duplicates was 1061. After primary and secondary screening 32 articles were selected. Regarding psychiatric disorders, the studies of ALA in schizophrenia are advanced being ALA administration related to the improvement of schizophrenia symptoms and side effects of antipsychotic medication. In neurological disorders, ALA as a supplement was effective in the prevention of Alzheimer disease progression. For stroke, the use of the supplement ALAnerv® (containing 300 mg ALA) presented important results, since it was observed a reversal of clinical parameters and oxidative imbalance in these patients. For other neurological conditions, such as encephalopathy, multiple sclerosis, traumatic brain injury, mitochondrial disorders and migraine, the results are still preliminary. Overall, there is a need of well-designed clinical trials to enhance the clinical evidences of ALA effects for the treatment of neurological and psychiatric conditions.

KEYWORDS:

Alpha-lipoic acid; Central nervous system; Neurological disorders; Psychiatric disorders

PMID:
30467770
DOI:
10.1007/s11011-018-0344-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center